MICHAEL HASSMAN: Open Payments
NPI 1922002765 · BERLIN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,712 in 112 payments from 29 companies in 2025. Trend: 2023 $1,539 · 2024 $2,931 · 2025 $1,712
Food & beverage: $1,712
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 9 | $254 |
| Lilly USA, LLC | 15 | $188 |
| Amgen Inc. | 14 | $139 |
| Kowa Pharmaceuticals America, Inc. | 7 | $106 |
| Alkermes, Inc. | 5 | $89 |
| Janssen Biotech, Inc. | 5 | $88 |
| ABBVIE INC. | 5 | $84 |
| Lundbeck LLC | 4 | $74 |
| PFIZER INC. | 8 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
Products named: REZDIFFRA, REXULTI, MOUNJARO, ZORYVE, VIVITROL, TREMFYA, OTEZLA, OMVOH.
Industry payments across NJ — which companies pay providers there.
